Analysts project Eli Lilly (LLY) to deliver 21%+ revenue growth and 40%+ adjusted earnings growth in 2026. Pressure from cash-pay competition and faster-than-expected generic entry led Jefferies to reduce the peak market estimate for the global obesity drug market to $80 billion by 2035. Despite revised projections, LLY is expected to see significant growth. In response to market demand, Eli Lilly announced plans to build a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania, focusing on injectable weight-loss drug production. The plant will start operations in 2031. Eli Lilly develops and commercializes medicines in various areas. Consider investing in LLY, but also explore AI stocks for potentially greater returns. Check out our report on the best short-term AI stock.

Read more at Yahoo Finance: Analysts Project Eli Lilly (LLY) to Deliver 21%+ Revenue Growth and 40%+ Adjusted Earnings Growth in 2026